[go: up one dir, main page]

PE20040640A1 - Compuestos de tiazol como inhibidores de la enzima gamma secretasa - Google Patents

Compuestos de tiazol como inhibidores de la enzima gamma secretasa

Info

Publication number
PE20040640A1
PE20040640A1 PE2003001021A PE2003001021A PE20040640A1 PE 20040640 A1 PE20040640 A1 PE 20040640A1 PE 2003001021 A PE2003001021 A PE 2003001021A PE 2003001021 A PE2003001021 A PE 2003001021A PE 20040640 A1 PE20040640 A1 PE 20040640A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
thiazol
difluoro
cycloalkyl
Prior art date
Application number
PE2003001021A
Other languages
English (en)
Inventor
Michael Leon Corman
Yuhpyng Liang Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20040640A1 publication Critical patent/PE20040640A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTOS DE TIAZOL DE FORMULA (I), DONDE A ES -C(=O)C(=O)-, -C(=O)NR9-, -C(=O)Z-, -C(=S)Z-, ENTRE OTROS; Z ES -CH2-, -CH(OH)-, -CH(OC(=O)R11)-, ENTRE OTROS; R1 ES ALQUILO(C1-C20), ALCOXI(C1-C20), CICLOALQUILO(C3-C8), CICLOALQUENILO(C4-C8), BI O TRICICLOALQUILO(C5-C11), ENTRE OTROS; R2 ES H, ALQUILO(C1-C4), -C(=O)(ALQUILO(C1-C4)), ARILO(C6-C10), ENTRE OTROS; R3 ES ALQUILO(C1-C6), ALQUENILO(C2-C6), ALQUINILO(C2-C6), -(ALQUILENO(C0-C4))-(CICLOALQUILO(C3-C6)), ENTRE OTROS; R4 ES H, D, F, ALQUILO(C1-C4) O R3 Y R4 FORMAN UN CICLOPROPILO, CICLOBUTILO, CICLOHEXILO, MORFOLINO, ENTRE OTROS; R6 ES -H, -ALQUILO(C1-C20), HALOGENO, -CN, -CF3, -C(=O)R11, ENTRE OTROS; R7 ES H, HALOGENO, -CN, -NO2, -CF3, ALQUILO (C1-C20), ALCOXI(C1-C20), O R6 Y R7 FORMAN UN ANILLO ARILO(C6-C10), CICLOALQUILO O CICLOALQUENILO(C6-C8), HETEROCICLOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-[2-(3,5-DIFLUORO-FENIL)-ACETILAMINO]-N-(4-FENIL-TIAZOL-2-IL)-PROPIONAMIDA, ESTER ETILICO DEL ACIDO 2-{2-[2-(3,5-DIFLUORO-FENIL)-ACETILAMINO]-PROPIONILAMINO}-4-FENIL-TIAZOL-5-CARBOXILICO, [5-(1-BUTILAMINO-ETIL)-4-METIL-TIAZOL-2-IL]-AMIDA DEL ACIDO 2-[2-(3,5-DIFLUORO-FENIL)-ACETAMINO]-PENTANOICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE. ESTOS COMPUESTOS INHIBEN LA PRODUCCION DE Aß-PEPTIDOS DEBIDO A SU ACTIVIDAD INHIBITORIA DE LA ENZIMA GAMMA-SECRETASA Y SON UTILES PARA EL TRATAMIENTO DE TRANSTORNOS NEURODEGENERATIVOS COMO EL MAL DE ALZHEIMER
PE2003001021A 2002-10-09 2003-10-07 Compuestos de tiazol como inhibidores de la enzima gamma secretasa PE20040640A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41740002P 2002-10-09 2002-10-09
US46320903A 2003-06-17 2003-06-17

Publications (1)

Publication Number Publication Date
PE20040640A1 true PE20040640A1 (es) 2004-09-15

Family

ID=35306299

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001021A PE20040640A1 (es) 2002-10-09 2003-10-07 Compuestos de tiazol como inhibidores de la enzima gamma secretasa

Country Status (28)

Country Link
US (1) US20040152747A1 (es)
EP (1) EP1551815A1 (es)
JP (1) JP2006504796A (es)
KR (1) KR20050070046A (es)
CN (1) CN1688557A (es)
AP (1) AP2005003274A0 (es)
AR (1) AR043051A1 (es)
AU (1) AU2003265068A1 (es)
BR (1) BR0314611A (es)
CA (1) CA2501803A1 (es)
CO (1) CO5550435A2 (es)
CR (1) CR7785A (es)
EC (1) ECSP055719A (es)
GT (1) GT200300219A (es)
IS (1) IS7738A (es)
MA (1) MA27451A1 (es)
MX (1) MXPA05002420A (es)
NL (1) NL1024499C2 (es)
NO (1) NO20052223L (es)
OA (1) OA12937A (es)
PA (1) PA8585001A1 (es)
PE (1) PE20040640A1 (es)
PL (1) PL376171A1 (es)
TN (1) TNSN05104A1 (es)
TW (1) TW200420550A (es)
UY (1) UY28011A1 (es)
WO (1) WO2004033439A1 (es)
ZA (1) ZA200502841B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
BRPI0409721A (pt) * 2003-05-12 2006-05-02 Pfizer Prod Inc compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos
JP2007501244A (ja) * 2003-08-06 2007-01-25 ファイザー・プロダクツ・インク 神経変性障害治療用オキサゾール化合物
WO2005073226A1 (fr) * 2004-01-16 2005-08-11 Sanofi-Aventis Derives d’acylaminothiazole, leur preparation et leur application en therapeutique
FR2873370B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
EP1709018B1 (fr) 2004-01-16 2011-07-20 Sanofi-Aventis Derives d'acylaminothiazole et leur application comme inhibiteurs de beta-amyloide
FR2865206B1 (fr) * 2004-01-16 2009-02-06 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2873374B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2865207B1 (fr) * 2004-01-16 2008-10-17 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
GEP20084420B (en) * 2004-03-23 2008-07-10 Pfizer Prod Inc Use of imidazole compounds for the treatment of neurodegenerative disorders
US7220865B2 (en) * 2004-04-01 2007-05-22 Pfizer Inc Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
US7384968B2 (en) * 2004-04-01 2008-06-10 Pfizer Inc. Thiazole-amine compounds for the treatment of neurodegenerative disorders
BRPI0515012A (pt) 2004-08-13 2008-07-01 Genentech Inc substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
KR20080015114A (ko) * 2005-05-24 2008-02-18 라보라뚜와르 세로노 에스. 에이. 티아졸 유도체 및 그것의 용도
FR2887879B1 (fr) * 2005-07-01 2008-09-26 Trophos Sa Nouveaux composes chimiques et leurs utilisations comme medicament,particulierement dans le traitement des maladies neurodegeneratives
CN101282941A (zh) * 2005-09-22 2008-10-08 辉瑞产品公司 用于治疗神经障碍的咪唑类化合物
CA2631750A1 (en) 2005-12-01 2007-06-07 The Scripps Research Institute Compositions and methods for inducing neuronal differentiation
EA200801716A1 (ru) * 2006-01-18 2009-04-28 Амген Инк. Тиазольные соединения и их применение
EP1918286B1 (en) * 2006-11-05 2011-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Thiazolhydrazides for treatment of neurodegenerative diseases
GB0701426D0 (en) * 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
US7919504B2 (en) * 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
WO2009011880A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
RU2401837C2 (ru) * 2008-05-19 2010-10-20 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) N-(2-тиазолил)амид 2-(2-оксо-3-индолинилиден)гидразино-4-оксо-4-фенил-2-бутеновой кислоты, обладающий противомикробной и анальгетической активностью
PE20110105A1 (es) 2008-07-15 2011-02-25 Novartis Ag Derivados de heteroarilo como inhibidores de dgat1
JP5705748B2 (ja) 2009-02-18 2015-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する複素環化合物
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2011088015A1 (en) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
JP5746764B2 (ja) 2010-07-22 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
CN102351854B (zh) * 2011-07-29 2014-06-04 华中科技大学 氨基噻唑衍生物及制备方法和医药用途
AU2014241065B2 (en) * 2013-03-14 2017-08-31 Merck Patent Gmbh Glycosidase inhibitors
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN103435573B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 苄基取代的噻唑并环己烷类化合物、其制备方法和用途
CN103408541B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
GB201401886D0 (en) 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
TW201906838A (zh) 2017-06-21 2019-02-16 日商第一三共股份有限公司 Ｅｐ３００／ｃｒｅｂｂｐ抑制劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021360A1 (en) * 1991-05-28 1992-12-10 Merck & Co., Inc. Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
BR9910092A (pt) * 1998-05-01 2002-01-22 Abbott Lab Inibidores de beta-aminoácido substituìdo de metionina aminopeptidase-2
CO5021134A1 (es) * 1998-05-01 2001-03-27 Abbott Lab Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina
AU6229699A (en) * 1998-10-26 2000-05-15 Sumitomo Pharmaceuticals Company, Limited Beta-amyloid formation inhibitors
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
IS7738A (is) 2005-03-10
NO20052223L (no) 2005-07-04
JP2006504796A (ja) 2006-02-09
PL376171A1 (en) 2005-12-27
CA2501803A1 (en) 2004-04-22
TNSN05104A1 (fr) 2007-05-14
NL1024499C2 (nl) 2004-10-13
GT200300219A (es) 2004-05-18
BR0314611A (pt) 2005-07-26
AP2005003274A0 (en) 2005-06-30
AU2003265068A1 (en) 2004-05-04
MA27451A1 (fr) 2005-07-01
AR043051A1 (es) 2005-07-13
OA12937A (en) 2006-10-13
PA8585001A1 (es) 2004-12-16
ZA200502841B (en) 2006-03-29
TW200420550A (en) 2004-10-16
NO20052223D0 (no) 2005-05-06
UY28011A1 (es) 2004-04-30
KR20050070046A (ko) 2005-07-05
NL1024499A1 (nl) 2004-04-13
CN1688557A (zh) 2005-10-26
ECSP055719A (es) 2005-07-06
US20040152747A1 (en) 2004-08-05
WO2004033439A1 (en) 2004-04-22
MXPA05002420A (es) 2005-10-05
CR7785A (es) 2005-07-08
CO5550435A2 (es) 2005-08-31
EP1551815A1 (en) 2005-07-13

Similar Documents

Publication Publication Date Title
PE20040640A1 (es) Compuestos de tiazol como inhibidores de la enzima gamma secretasa
PE20051155A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
CO5700824A2 (es) Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20090041A1 (es) Derivados de triazol como inhibidores de la biosintesis de leucotrienos
PE20041016A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20030086A1 (es) Derivados de acidos tiofen dicarboxilicos como inhibidores de histona desacilasa (hdca)
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
BRPI0417110A (pt) inibidores de fosfodiesterase 4, incluindo análogos de diarilamina n-substituìdos, composto, composição farmacêutica, método para aumentar a cognição em um paciente no qual tal aumento é desejado, método de tratamento de um paciente que sofre de degeneração ou declìnio da cognição, método para o tratamento de um paciente que tem uma doença que envolve nìveis reduzidos de camp, método de inibição da atividade da enzima pde4 em uma paciente, método de tratamento de um paciente que sofre de degeneração da memória devido a uma doença neurodegenerativa, método de tratamento de um paciente que sofre de degeneração da memória devida a um distúrbio neurodegenerativo agudo, método de tratamento de um paciente que sofre de uma doença alérgica ou inflamatória, método para o tratamento de um paciente que sofre de esquizofrenia, método para o tratamento de um paciente que sofre de psicose caracterizada por nìveis elevados pde4, sendo que a dita psicose é uma forma de depressão
PE20061303A1 (es) Composicion farmaceutica que comprende oxaprozina
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
MA30456B1 (fr) Nouveau dérivé de coumarine présentant une activité anti-tumorale.
WO2005012269A8 (ja) 新規アゾール化合物
MA32965B1 (fr) Derives de sulfonamides
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
NZ602099A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
CA2581865A1 (en) Indazolone derivatives as 11b-hsd1 inhibitors
AU2007234022A1 (en) Ceramide kinase modulation
AR047671A1 (es) Compuestos de arilnitrona 2-sustituidos y 4-sustituidos
PE20061013A1 (es) Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias
PE20011290A1 (es) Derivados de benzotiazol como inhibidores del factor de necrosis tumoral (tnf) y/o fosfodiesterasa iv (pdeiv)
PE20091102A1 (es) Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
PL376728A1 (pl) Indole użyteczne do leczenia chorób związanych z receptorem androgenowym
HU229137B1 (en) 8,8a-dihydro-indeno[1,2-d]thiazole derivatives having sulphoneamid- or sulphone substitutents in the 2 position, method for production thereof and use thereof as a medicament
PE20090280A1 (es) Pirazol-pirrolidinas como inhibidores de gamma secretasa
PH12018502012A1 (en) Griseofulvin compound

Legal Events

Date Code Title Description
FA Abandonment or withdrawal